709 related articles for article (PubMed ID: 33434602)
1. Efficacy and safety of the glucagon-like peptide-1 receptor agonist oral semaglutide in patients with type 2 diabetes mellitus: A systematic review and meta-analysis.
Li J; He K; Ge J; Li C; Jing Z
Diabetes Res Clin Pract; 2021 Feb; 172():108656. PubMed ID: 33434602
[TBL] [Abstract][Full Text] [Related]
2. The safety and efficacy of once-weekly glucagon-like peptide-1 receptor agonist semaglutide in patients with type 2 diabetes mellitus: a systemic review and meta-analysis.
Li X; Qie S; Wang X; Zheng Y; Liu Y; Liu G
Endocrine; 2018 Dec; 62(3):535-545. PubMed ID: 30101378
[TBL] [Abstract][Full Text] [Related]
3. Oral semaglutide for type 2 diabetes: A systematic review and meta-analysis.
Avgerinos I; Michailidis T; Liakos A; Karagiannis T; Matthews DR; Tsapas A; Bekiari E
Diabetes Obes Metab; 2020 Mar; 22(3):335-345. PubMed ID: 31637820
[TBL] [Abstract][Full Text] [Related]
4. Cost-effectiveness of oral semaglutide added to current antihyperglycemic treatment for type 2 diabetes.
Guzauskas GF; Rind DM; Fazioli K; Chapman RH; Pearson SD; Hansen RN
J Manag Care Spec Pharm; 2021 Apr; 27(4):455-468. PubMed ID: 33769850
[No Abstract] [Full Text] [Related]
5. Efficacy and safety of oral semaglutide with flexible dose adjustment versus sitagliptin in type 2 diabetes (PIONEER 7): a multicentre, open-label, randomised, phase 3a trial.
Pieber TR; Bode B; Mertens A; Cho YM; Christiansen E; Hertz CL; Wallenstein SOR; Buse JB;
Lancet Diabetes Endocrinol; 2019 Jul; 7(7):528-539. PubMed ID: 31189520
[TBL] [Abstract][Full Text] [Related]
6. Clinical review of the efficacy and safety of oral semaglutide in patients with type 2 diabetes considered for injectable GLP-1 receptor agonist therapy or currently on insulin therapy.
Wright EE; Aroda VR
Postgrad Med; 2020 Nov; 132(sup2):26-36. PubMed ID: 32815423
[TBL] [Abstract][Full Text] [Related]
7. Semaglutide for type 2 diabetes mellitus: A systematic review and meta-analysis.
Andreadis P; Karagiannis T; Malandris K; Avgerinos I; Liakos A; Manolopoulos A; Bekiari E; Matthews DR; Tsapas A
Diabetes Obes Metab; 2018 Sep; 20(9):2255-2263. PubMed ID: 29756388
[TBL] [Abstract][Full Text] [Related]
8. Efficacy and safety of oral semaglutide in patients with type 2 diabetes and moderate renal impairment (PIONEER 5): a placebo-controlled, randomised, phase 3a trial.
Mosenzon O; Blicher TM; Rosenlund S; Eriksson JW; Heller S; Hels OH; Pratley R; Sathyapalan T; Desouza C;
Lancet Diabetes Endocrinol; 2019 Jul; 7(7):515-527. PubMed ID: 31189517
[TBL] [Abstract][Full Text] [Related]
9. Oral semaglutide versus subcutaneous liraglutide and placebo in type 2 diabetes (PIONEER 4): a randomised, double-blind, phase 3a trial.
Pratley R; Amod A; Hoff ST; Kadowaki T; Lingvay I; Nauck M; Pedersen KB; Saugstrup T; Meier JJ;
Lancet; 2019 Jul; 394(10192):39-50. PubMed ID: 31186120
[TBL] [Abstract][Full Text] [Related]
10. Efficacy and safety of once-weekly semaglutide for the treatment of type 2 diabetes: Protocol for a systematic review and meta-analysis.
Shi FH; Li H; Cui M; Zhang ZL; Gu ZC; Liu XY
Medicine (Baltimore); 2018 Apr; 97(16):e0420. PubMed ID: 29668601
[TBL] [Abstract][Full Text] [Related]
11. Oral semaglutide in type 2 diabetes mellitus: Comprehensive review, critical appraisal and clinical consideration of its use in India.
Singh AK; Singh R; Misra A
Diabetes Metab Syndr; 2022 Mar; 16(3):102436. PubMed ID: 35245858
[TBL] [Abstract][Full Text] [Related]
12. The effect of semaglutide on blood pressure in patients with type-2 diabetes: a systematic review and meta-analysis.
Wu W; Tong HM; Li YS; Cui J
Endocrine; 2024 Mar; 83(3):571-584. PubMed ID: 38097902
[TBL] [Abstract][Full Text] [Related]
13. Efficacy and safety of once-weekly semaglutide versus once-daily sitagliptin as an add-on to metformin, thiazolidinediones, or both, in patients with type 2 diabetes (SUSTAIN 2): a 56-week, double-blind, phase 3a, randomised trial.
Ahrén B; Masmiquel L; Kumar H; Sargin M; Karsbøl JD; Jacobsen SH; Chow F
Lancet Diabetes Endocrinol; 2017 May; 5(5):341-354. PubMed ID: 28385659
[TBL] [Abstract][Full Text] [Related]
14. The efficacy and safety of oral semaglutide for glycaemic management in adults with type 2 diabetes compared to subcutaneous semaglutide, placebo, and other GLP-1 RA comparators: A systematic review and network meta-analysis.
Alhindi Y; Avery A
Contemp Clin Trials Commun; 2022 Aug; 28():100944. PubMed ID: 35812819
[TBL] [Abstract][Full Text] [Related]
15. Oral Semaglutide: First-in-Class Oral GLP-1 Receptor Agonist for the Treatment of Type 2 Diabetes Mellitus.
Cowart K
Ann Pharmacother; 2020 May; 54(5):478-485. PubMed ID: 31744308
[No Abstract] [Full Text] [Related]
16. Evaluation of the Cost Per Patient Achieving Treatment Targets with Oral Semaglutide: A Short-Term Cost-Effectiveness Analysis in the United States.
Hunt B; Hansen BB; Ericsson Å; Kallenbach K; Ali SN; Dang-Tan T; Malkin SJP; Valentine WJ
Adv Ther; 2019 Dec; 36(12):3483-3493. PubMed ID: 31650514
[TBL] [Abstract][Full Text] [Related]
17. Dose-response, efficacy, and safety of oral semaglutide monotherapy in Japanese patients with type 2 diabetes (PIONEER 9): a 52-week, phase 2/3a, randomised, controlled trial.
Yamada Y; Katagiri H; Hamamoto Y; Deenadayalan S; Navarria A; Nishijima K; Seino Y;
Lancet Diabetes Endocrinol; 2020 May; 8(5):377-391. PubMed ID: 32333875
[TBL] [Abstract][Full Text] [Related]
18. Semaglutide: The Newest Once-Weekly GLP-1 RA for Type 2 Diabetes.
Tuchscherer RM; Thompson AM; Trujillo JM
Ann Pharmacother; 2018 Dec; 52(12):1224-1232. PubMed ID: 29932006
[TBL] [Abstract][Full Text] [Related]
19. Clinical review of the efficacy and safety of oral semaglutide in patients with type 2 diabetes compared with other oral antihyperglycemic agents and placebo.
Lavernia F; Blonde L
Postgrad Med; 2020 Nov; 132(sup2):15-25. PubMed ID: 32815436
[TBL] [Abstract][Full Text] [Related]
20. Efficacy and safety of oral semaglutide in type 2 diabetes mellitus: A systematic review and meta-analysis.
Li A; Su X; Hu S; Wang Y
Diabetes Res Clin Pract; 2023 Apr; 198():110605. PubMed ID: 36871874
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]